Featured news from NHIVNA
HIV-related news from NAM
French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection
Liz Highleyman, 2013-03-05 13:10:00
Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV co-infected prior non-responders in a pair of French studies presented yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
The advent of direct-acting antiviral agents for hepatitis C (HCV) has ushered in a new treatment paradigm. While many patients and providers await interferon-free regimens, some people with chronic hepatitis C have progressive liver disease and require treatment now. But some people who need effective treatment the most have factors associated with poorer response and reduced tolerance of side-effects, including HIV/HCV co-infection, advanced liver fibrosis or cirrhosis, obesity, certain genetic factors and a history of prior treatment failure.
ANRS, the French National Agency for AIDS Research, designed the phase II BocepreVIH and TelapreVIH trials to test the safety and efficacy of triple therapy using the HCV protease inhibitors boceprevir (Victrelis) or telaprevir (Incivo or Incivek) with pegylated interferon plus ribavirin for co-infected people who did not respond to prior interferon-based treatment. Although the study designs, interventions and patient populations are similar, they were not designed to compare one drug versus the other.
Source:1
